Nivolumab-induced hepatitis in a patient treated for malignant melanoma

Article Properties
  • DOI (url)
    10.36290/xon.2020.033
  • Publication Date
    2020/06/02
  • Journal
    Onkologie
  • Indian UGC (journal)
  • Refrences
    10
  • Citations
    1
  • Jan Šustr
  • Ondřej Fiala
  • Samuel Vokurka
  • Jindřich Fínek
  • Jana Kulhánková
  • Karel Balihar
  • Lukáš Kielberger
Cite
Šustr, Jan, et al. “Nivolumab-Induced Hepatitis in a Patient Treated for Malignant Melanoma”. Onkologie, vol. 14, no. Suppl.B, 2020, pp. 34-36, https://doi.org/10.36290/xon.2020.033.
Šustr, J., Fiala, O., Vokurka, S., Fínek, J., Kulhánková, J., Balihar, K., & Kielberger, L. (2020). Nivolumab-induced hepatitis in a patient treated for malignant melanoma. Onkologie, 14(Suppl.B), 34-36. https://doi.org/10.36290/xon.2020.033
Šustr J, Fiala O, Vokurka S, Fínek J, Kulhánková J, Balihar K, et al. Nivolumab-induced hepatitis in a patient treated for malignant melanoma. Onkologie. 2020;14(Suppl.B):34-6.
Refrences
Title Journal Journal Categories Citations Publication Date
Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma Internal Medicine
  • Medicine: Medicine (General)
  • Medicine: Internal medicine
  • Medicine: Medicine (General)
 21 2018
Histologic patterns of liver injury induced by anti-PD-1 therapy

 Gastroenterology Report
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Internal medicine: Specialties of internal medicine: Diseases of the digestive system. Gastroenterology
  • Medicine: Medicine (General)
 20 2019
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis Expert Opinion on Drug Safety
  • Medicine: Public aspects of medicine: Toxicology. Poisons
  • Medicine: Therapeutics. Pharmacology
 40 2015
10.1200/JCO.2012.41.6750
10.1200/JCO.2010.32.2206
Citations
Title Journal Journal Categories Citations Publication Date
Nivolumab Reactions Weekly 2021